On November 29, 2016 Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) reported that results from two non-small cell lung cancer ("NSCLC") clinical studies will be presented at WCLC in Vienna, Austria, from December 4 to 7, 2016 (Press release, Hutchison China MediTech, NOV 29, 2016, View Source [SID1234516838]). Results from the positive Phase II third-line NSCLC clinical trial of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors ("VEGFR"), will be detailed in an oral presentation. Results from the ongoing Phase Ib first-line NSCLC clinical trial of epitinib, a highly selective inhibitor of the epidermal growth factor receptor ("EGFR") designed to optimize brain penetration, will also be presented.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In September 2015, Chi-Med announced that the fruquintinib Phase II NSCLC clinical trial had successfully achieved its primary endpoint. The oral and poster presentations will include more mature data than those included in the following fruquintinib and epitinib study abstracts.

The results of the two studies will be presented in detail at WCLC as follows:

Type: Oral Presentation
Title: A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Shun Lu
Abstract: #4571
Session: OA11 – Angiogenesis in Advanced Lung Cancer, Oral Session
Date & Time: Tuesday, December 6, 2016 (11:00 AM – 12:30 PM)
Type: Poster Presentations
Title: A Phase I Dose Expansion Study of Epitinib to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm+) NSCLC Patients with Brain Metastasis
Authors: Qing Zhou, et al.
Abstract: #4253
1st Session: JCES01 Joint IASLC–Chinese Society for Clinical Oncology /
Chinese Alliance Against Lung Cancer Session (ID 413)
Date & Time: Sunday, December 4, 2016 (10:30 AM – 11:30 AM)
2nd Session: 07. Advanced NSCLC
P2.03b – Poster Session with Presenters Present (ID 465)
Date & Time: Tuesday, December 6, 2016 (2:30 PM – 3:45 PM)
The WCLC presentations will be made available for download at www.chi-med.com/news on the following day.

Organized by the International Association for the Study of Lung Cancer (IASLC) and held annually, WCLC is a global, multidisciplinary scientific forum for sharing current knowledge and research progress in lung cancer. For more information, please visit: wclc2016.iaslc.com.